Antibiotic resistance is no longer a concern for the distant future but is a pressing issue, both globally and in Nepal. As part of global effort to preserve the effectiveness of antibiotics, the Global Antibiotic Resistance Partnership (GARP)-Nepal was established to doc...ument the current state of antibiotic access, use and resistance in the country, and to identify policies and actions that could set a course for antibiotic sustainability.
more
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
first issued 18 August 2022
On 14 August 2024, the Director-General of the World Health Organization determined that the upsurge of mpox in a growing number of countries in Africa constitutes a new public health emergency of international concern (PHEIC) under the International Health Regulations (IHR) (2005)
Mood disorders
Chapter E.4
2018 edition
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV‑2) causing coronavirus disease 2019 (COVID-19) has reached pandemic levels;
Patients with cardiovascular (CV) risk factors and established cardiovascular disease (CVD) represent a vulnerable population when suffering from COVID-19;
Patien...ts with cardiac injury in the context of COVID-19 have an increased risk of morbidity and mortality
more
Standard Treatment Guideline
Together we can Prevent and Control the World's Most Common Diseases
Objectives of the training manual
(1) To improve knowledge of NCD trends, burdens, as well as systems for management and monitoring of NCD services for Township Medical Officers (TMOs), Township Public Health Officers (TP...HOs), Medical Officers (MOs). The manual can also be used for training of Basic Health staff (BHS), TMOs, TPHOs and MOs,
(2) To equip trainers to train BHS to conduct PEN protocols at the primary care level health centers,
(3) To equip trainers to train in processes to conduct PEN scaling up monitoring , supervision and evaluation activities.
more
Developmental disorders
Chapter C.3
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Reprinted from Australian Family Physician Vol. 39, No. 10, october 2010